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Abstract:  
A simple, accurate, precise, sensitive and stability indicating RP-HPLC method has been developed for the 
determination of Pazopanib hydrochloride in bulk drug and pharmaceutical dosage form, in which separations are 
done using develosil C18, 5μm, 150 × 4.6mm i.d. column at a flow rate of 1.0mL/min with an injection volume of 
20μL. The beer’s law was obeyed over the concentration range of 5 - 35μg/mL. The correlation coefficient was 
found to be 0.996 and it showed good linearity, reproducibility, precision in this concentration range. The aim of 
this paper was to develop and validate the stability indicating RP-HPLC method for the determination of Pazopanib 
hydrochloride in bulk and pharmaceutical dosage forms. The % recovery values were found to be within the limits, 
which showed that the method was accurate. The LOD and LOQ were calculated using statistical methods. The % 
RSD values were less than 2. The developed method was successfully applied for determination of Pazopanib 
hydrochloride in pharmaceutical dosage form. The results obtained are in good agreement with those obtained by 
using the standard method.  
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INTRODUCTION:  
Pazopanib is presented as the hydrochloride salt, with 
the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-
6-yl) methylamino] – 2 pyrimidinyl] amino] -2- 
methyl benzene sulfonamide mono hydrochloride. It 
has the molecular formula C21H23N7O2S•HCl and a 
molecular weight of 473.99. Pazopanib is a multi-
tyrosine kinase inhibitor of vascular endothelial 
growth factor receptor (VEGFR)-1, VEGFR-2, 
VEGFR-3, platelet-derived growth factor receptor 
(PDGFR)-α and -β, fibroblast growth factor receptor 
(FGFR) -1 and -3, cytokine receptor (Kit), 
interleukin-2 receptor inducible T-cell kinase (Itk), 
leukocyte-specific protein tyrosine kinase (Lck), and 
transmembrane glycoprotein receptor tyrosine kinase 
(c-Fms). In vitro, pazopanib inhibited ligand-induced 
autophosphorylation of VEGFR-2, Kit and PDGFR-
 receptors1-3. According to the literature survey4-7 
it was found that few analytical methods on HPLC, 
HPTLC, UPLC and UV Spectrophotometer were 
reported for the estimation of Pazopanib 
hydrochloride in bulk drug and formulations. Hence 
there is need to develop and validate an analytical 
method to estpazopanib hydrochloridee the drug. The 
objective of the proposed method is to develop 
simple, accurate, precise, stability indicating RP-
HPLC method for the estpazopanib hydrochlorideion 
of Pazopanib hydrochloridein pharmaceutical dosage 
form.  
 
MATERIAL AND METHODS:  
Reagents and Chemicals 
 Pazopanib hydrochloride working standard was 
procured from Mylan Laboratories, Hyderabad, and 
Telangana. Pazopanib hydrochloride 400 mg tablets 
(Votrient®) were purchased from local pharmacy. 
Purified water was obtained from Millipore system. 
Acetonitrile (HPLC grade) and potassium dihydrogen 
orthophosphate were obtained from Loba Chem, 
Mumbai, and Sd fine-Chem ltd, Mumbai, 
respectively. All other chemicals used in the analysis 
were AR grade.  
Instrumental and analytical conditions  
The HPLC analysis was performed using a HITACHI 
L2130 with D Elite 2000 Software with Isocratic 
with UV-Visible Detector (L-2400). Column used 
was develosil C18, 5μm, 150 x 4.6 mm i.d. UV 
detection was performed at 268nm. The injection 
volume of sample was 20μL. An isocratic mobile 
phase containing Acetonitrile and 0.05M potassium 
dihydrogen orthophosphate buffer (30:70%v/v), at 
the pH 2.5 with O-phosphoric acid was carried out 
with the flow rate of 1.0mL/min. Column was 
maintained at room temperature.  
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Experimental  
Mobile Phase Preparation  
Mixture of Acetonitrile and Phosphate buffer, pH 2.5 
in the ratio of 30:70(%v/v) respectively was used.  
Preparation of Standard Solution  
Accurately weighed 50mg of Pazopanib 
hydrochlorideworking standard was transferred into 
50mL volumetric flask. About 40mL of diluent 
(mobile phase) was added and sonicated to dissolve. 
The volume was made up with diluent and mixed. 
0.1mL of this solution was diluted to 10mL with 
mobile phase and mixed.  
Preparation of Sample Solution  
Four capsules were weighed accurately and the 
average weight was calculated.  
Capsules were opened, fine powder was collected 
and equivalent to 50mg of Pazopanib 
hydrochloridesample was weighed and transferred 
into 50mL volumetric flask. 40mL of diluent was 
added and sonicated for 30min with intermediate 
shaking. Volume was made up with diluent. The 
above solution was centrifuged for 10min at 
8000rpm. 0.1mL of this solution was diluted to 10mL 
with mobile phase and mixed. The solution was 
filtered through 0.45 μm filter.  
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Method Development 
A develosil C18, 5μm, 150 x 4.6 mm i.d as a 
stationary phase with a mobile phase of Acetonitrile 
and Phosphate buffer, pH 3.1 (25:75) at a flow rate 
1.0mL/min and a detection wavelength of 268nm 
afforded the best separation of drug. The standard 
solution and sample solution prepared as above were 
injected into the 20μL loop and the chromatograms 
were recorded as shown in the “Fig. 2” and “Fig. 3” 
respectively. The retention time of drug, Pazopanib 
hydrochloride was found to be 2.67mins. The amount 
of drug present in sample was calculated.  
Method Validation  
The proposed stability indicating method has been 
developed and validated for the determination of 
Pazopanib hydrochloride in pharmaceutical dosage 
forms. According to International Conference on 
Harmonization (ICH) guidelines13 - 14, validation of 
the method was carried out by using specificity, 
accuracy, linearity, suitability, LOD, LOQ, precision 
and stability studies.  
System suitability  
A standard solution was prepared by using Pazopanib 
hydrochloride working standard as per test method 
and was injected 5 times into the HPLC system. The 
system suitability parameters were evaluated from 
the Resolution, USP tailing and USP plate count 
values obtained from standard chromatograms as 
shown in Table 1.  
Specificity  
Specificity was evaluated by injecting standard 
solution and placebo solution individually into HPLC 
system.  
Linearity of test solution  
A series of solutions are prepared from standard 
stock solution at concentration levels from 05-
35μg/ml for Pazopanib hydrochloride.  
Accuracy  
Drug assay was performed in triplicate as per test 
method with equivalent amount of drugs into each 
volumetric flask for each spike level to get the 
concentration of drugs equivalent to 80%, 100% and 
120% of the labeled amount as the test method.  
 
Precision  
Repeatability  
Repeatability of method was evaluated by calculating 
the %RSD of peak areas of five replicate injections 
for the standard concentration (10ppm) of drug.  
Ruggudness  
The ruggedness was also evaluated by analyzing five 
samples of drug by two analysts in the same 
laboratory using different HPLC systems.  
Limit of Detection and Limit of Quantitation  
The parameters LOD and LOQ were determined on 
the basis of standard deviation and slope of the 
regression equation.  
Forced degradation studies  
The forced degradation study was performed to 
determine the specificity and stability indicating 
property of developed method. The drug was 
deliberately subjected to stress conditions such as 
acidic condition, alkaline condition, oxidation 
condition and thermal condition. All the solutions for 
degradation were prepared by dissolving drug in 
diluent to get an initial concentration of 1mg/mL and 
filtered. Acid decomposition was carried out in 1N 
hydrochloric acid and alkaline degradation was 
conducted using 1N sodium hydroxide and kept aside 
for 24 hours. Solutions for oxidative degradation 
were prepared using 3% hydrogen peroxide at a 
concentration of 1mg/mL of Pazopanib hydrochloride 
and kept aside for 24 hours. For thermal degradation 
study, the drug solution 1mg/mL was heated in 
calibrated oven at 80ºC for 8 hours, cooled and used. 
These solutions are injected into the HPLC system 
and values were noted.  
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RESULTS AND DISCUSSION:  
Selection of detection wavelength  
From the UV spectrum, suitable wavelength 
considered for monitoring the drug was 268nm as 
shown in “Fig. 4”. A stability indicating RP-HPLC 
method was developed by using an Develosil C18 
(150mm × 4.6mm, 5μm particle size) as a stationary 
phase with a mobile phase of Acetonitrile and 
Phosphate buffer, pH 2.5 (30:70) at a flow rate 
1.0mL/min and a detection wavelength of 268nm 
afforded the best separation of drug. The injection 
volume is 20μL and retention time for Pazopanib 
hydrochloride is 2.67mins. The method was validated 
according to ICH guidelines for various parameters 
like accuracy, precision, linearity, specificity, 
ruggedness, LOD, LOQ and stability studies. 
Linearity was obtained in the concentration range of 
05-35μg/mL with correlation coefficient (r) of 0.999. 
The %recovery was found to be 99.74%. The %RSD 
for precision was found to be 0.76 and for ruggedness 
it was found to be 0.53.  
 
CONCLUSION:  
A simple, precise, accurate, rapid, economical, 
stability indicating RP-HPLC method for estimation 
of Pazopanib hydrochloride has been developed and 
validated as per ICH guidelines. The proposed 
method shows good agreement with all validation 
parameters. The optimized method is precise, 
accurate, specific, rugged, and a linear relation is 
observed between the concentration and the result. 
The developed method can be used for the analysis of 
routine quality control sample.  
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